Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.30 |
| ▸ | JAK3 | P52333 | 2/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21083338 | 0.82 | CYP1A2 (0.42) | TGFBR1 | |
| SCHEMBL22955470 | 0.81 | EIF2AK4 (0.36) | EIF2AK4TGFBR1 | |
| SCHEMBL8607829 | 0.80 | TGFBR1 (0.37) | TGFBR1 | |
| SCHEMBL8608885 | 0.80 | EIF2AK4 (0.33) | RXRAEIF2AK4 | |
| SCHEMBL8608539 | 0.79 | EIF2AK4 (0.31) | EIF2AK4 | |
| SCHEMBL8609368 | 0.75 | KDM4E (0.41) | RXRA | |
| SCHEMBL8606054 | 0.74 | PRMT5 (0.32) | — | |
| SCHEMBL8607789 | 0.74 | — | — | |
| SCHEMBL9753498 | 0.73 | — | — | |
| SCHEMBL19737585 | 0.72 | EIF2AK4 (0.39) | RXRAEIF2AK4TGFBR1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032242-A1 | AROMATIC HETEROCYCLIC SUBSTITUTED OLEFIN COMPOUND, PREPARATION METHOD FOR SAME, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032242-A1 | AROMATIC HETEROCYCLIC SUBSTITUTED OLEFIN COMPOUND, PREPARATION METHOD FOR SAME, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF | ALK, ALKBH5, ALKBH3 | RXRA 1849/4885EIF2AK4 3726/4885TGFBR1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.